mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
The benefit of ACE inhibitors extends even to those who have to commence dialysis to treat their kidney disease, and may give sufficient benefit to allow the discontinuation of renal replacement therapy.
Curium ion in solution almost always has a +3 oxidation state, the most stable oxidation state for curium. A +4 oxidation state is seen mainly in a few solid phases, such as CmO2 and CmF4. Aqueous curium(IV) is only known in the presence of strong oxidizers such as potassium persulfate, and is easily reduced to curium(III) by radiolysis and even by water itself. The chemical behavior of curium is different from the actinides thorium and uranium, and is similar to americium and many lanthanides. In aqueous solution, the Cm3+ ion is colorless to pale green; Cm4+ ion is pale yellow. The optical absorption of Cm3+ ion contains three sharp peaks at 375.4, 381.2 and 396.5 nm and their strength can be directly converted into the concentration of the ions. The +6 oxidation state has only been reported once in solution in 1978, as the curyl ion (CmO2+2): this was prepared from beta decay of americium-242 in the americium(V) ion 242AmO+2. Failure to get Cm(VI) from oxidation of Cm(III) and Cm(IV) may be due to the high Cm4+/Cm3+ ionization potential and the instability of Cm(V). Curium ions are hard Lewis acids and thus form most stable complexes with hard bases. The bonding is mostly ionic, with a small covalent component. Curium in its complexes commonly exhibits a 9-fold coordination environment, with a tricapped trigonal prismatic molecular geometry.
Abbi Jacobson as Shira Schwooper, the middle of the Schwooper children, and sole daughter of Naomi and Elliot. Born in August 1984, Shira is a lesbian and is married to Kendra, with whom she raises twin boys, Walter and Benjamin, and lives in Oakland, California. Shira is blunt, sardonic, stubborn, and easily holds grudges, but she’s nonetheless still compassionate and loves her family, and has a loving healthy relationship with her wife. As a child, Shira was best friends with Rachel "Baby" Feldstein, and had a romantic relationship with Rachel in high school. However, after catching her making out with a man, Shira discovers Rachel saw her as a fling and feels betrayed, which ends their friendship. Shira cannot conceive children due to primary ovarian insufficiency, so Kendra bears the couple's children. Nicole Byer as Kendra Hooper, a lesbian and Shira's wife, who converts to Judaism as an adult after lying about being Jewish to cover up for a work absence during Rosh Hashanah. Born in 1982, Kendra is more grounded than her wife and loves her in spite of her stubborn tendencies. Kendra works as a senior manager for B.J Banana Fingers, a children's entertainment fast-food chain similar to Chuck E. Cheese. She gained her role due to her being a former workaholic who over-exerted herself—a habit she picked up from her father—after being accepted into a managerial training program when she was a floor manager. Kendra fired an employee who helped her as a child in order to gain a higher position by setting her up, which Kendra will have to live with.
Sources: en.wikipedia.org
They were involved in the Kosovo War helping KLA guerillas behind Serbian lines. According to Albanian sources one SAS sergeant was killed by Serbian special forces. The Gulf War, in which A, B and D squadrons deployed, was the largest SAS mobilisation since the Second World War, also notable for the failure of the Bravo Two Zero mission. In Sierra Leone it took part in Operation Barras, a hostage rescue operation, to extract members of the Royal Irish Regiment. Following the September 11 attacks on the United States by al-Qaeda in 2001, two squadrons of 22 SAS, later reinforced by members of both the Territorial SAS units, deployed to Afghanistan as part of the Coalition invasion at the start of the War in Afghanistan, to dismantle and destroy al-Qaeda and to deny it a safe base of operations in Afghanistan by removing the Taliban from power in the war on terror. The Regiment carried out Operation Trent, the largest operation in its history, which included its first wartime HALO parachute jump. Following the invasion, the Regiment continued to operate in Afghanistan against the Taliban and other insurgents until 2006, when its deployment to Iraq became its focus of operations, until 2009 when the SAS redeployed to Afghanistan. The regiment took part in the Iraq War, notably carrying out operations in Iraq before the 2003 invasion.
Mutations in the GSS gene cause glutathione synthetase deficiency. This gene provides instructions for making the enzyme glutathione synthetase. This enzyme is involved in a process called the gamma-glutamyl cycle, which takes place in most of the body's cells. This cycle is necessary for producing a molecule called glutathione. Glutathione protects cells from damage caused by unstable oxygen-containing molecules, which are byproducts of energy production. Glutathione is called an antioxidant because of its role in protecting cells from the damaging effects of these unstable molecules which are byproducts of energy production. Mutations in the GSS gene prevent cells from making adequate levels of glutathione, leading to the signs and symptoms of glutathione synthetase deficiency. This disorder is inherited in an autosomal recessive pattern, which means the defective gene is located on an autosome, and two copies of the gene - one from each parent - are required to be born with the disorder. The parents of an individual with an autosomal recessive disorder each carry one copy of the defective gene, but usually are not affected by the disorder.
It has since been elucidated that androgens like testosterone and dihydrotestosterone (DHT) function as trophic factors for the prostate gland, stimulating cell division and proliferation and producing tissue growth and glandular enlargement, which, in the context of prostate cancer, results in stimulation of tumors and a considerable acceleration of disease progression. As a result of these discoveries, androgen deprivation therapy (ADT), via a variety of modalities including surgical castration, high-dose estrogens, SAAs, GnRH analogues, NSAAs, and androgen biosynthesis inhibitors (e.g., abiraterone acetate), has become the mainstay of treatment for prostate cancer. Although ADT can shrink or stabilize prostate tumors and hence significantly slow the course of prostate cancer and prolong life, it is not generally curative. While effective in slowing the progression of the disease initially, most advanced prostate cancer patients eventually become resistant to ADT and prostate cancer growth starts to accelerate again, in part due to progressive mutations in the androgen receptor (AR) that result in the transformation of drugs like bicalutamide from AR antagonists to agonists. A few observations form the basis of the reasoning behind combined androgen blockade (CAB), in which castration and an NSAA are combined. It has been found that very low levels of androgens, as in castration, are able to significantly stimulate growth of prostate cancer cells and accelerate disease progression.
Elena Galoppini, Italian chemist and professor at Rutgers University–Newark whose research focuses on the development of redox- and photo-active molecules to modify surfaces. Juliet Gerrard, New Zealand chemist and Prime Minister's Chief Science Advisor in the administration of Jacinda Ardern. Clare Grey, British chemist pioneering the use of nuclear magnetic resonance spectroscopy to study battery technology. Awarded the Körber European Science Prize in 2021. Professor at the University of Cambridge. Paula T. Hammond, American chemical engineer focusing on macromolecular design and synthesis of materials for drug delivery systems, particularly in relation to cancer, immunology, and immunotherapy. Professor at MIT. Jeanne Hardy, American biophysicist and chemical biologist. Known for her work in the design of allosteric binding sites and control elements into human proteases. Professor at the University of Massachusetts. Geraldine Harriman, American Organic Chemist. Developed Firsocostat. Chief Scientific Officer and co-founder of HotSpot. Rachel Haurwitz, American biochemist and structural biologist. Her work regards CRISPR based technologies, she is a cofounder of Caribou Biosciences, a genome editing and cell therapy development company. Kim Eunkyoung, South Korean materials chemist known for her work in electrochromic (EC) materials design Katja Loos, German polymer chemist working on the design, synthesis, and characterisation of novel and sustainable polymeric materials and macromolecules. Chair of the board of the Zernike Institute for Advanced Materials.
Sources: en.wikipedia.org
Immunomodulators Inhibitors of protein kinases Opioids Analgesics Treatment of benign prostatic hyperplasia Antiadrenergic drugs Hormonal treatments Diuretics Antiretroviral therapy Antihistamines Antidepressants *"For most of the drugs that are likely to affect spermatogenesis and/or sperm parameters, the levels of scientific evidence are still insufficient (with the exception of Sirolimus, Sulfasalazine, exogenous testosterone, Finasteride and Cyproterone acetate, for which the levels of evidence are higher). In some cases, data in men do not even exist, and the toxicity of a drug for the male reproductive organs is determined solely on the basis of animal models." **"For a certain number of pharmaceutical molecules that are likely to affect the sexual function of men being treated, the actual imputability of the drug is often difficult to pinpoint owing to the effect of the illness itself on sexuality (cardiovascular disease and erectile dysfunction; depressive illness and loss of desire, etc.)" Furthermore, hyperthyroidism, an excess of thyroid hormones, has been associated with reduced semen volume, reduced sperm density, motility, and morphology. Studies in humans show that an excess of circulating thyroid hormones during thyrotoxicosis results in asthenozoospermia, oligozoospermia, and teratozoospermia. These abnormalities frequently associate with semen alterations like reduced semen volume.
A variety of medical and psychological conditions have been misdiagnosed as anorexia nervosa; in some cases the correct diagnosis was not made for more than ten years. The distinction between binge purging anorexia, bulimia nervosa and Other Specified Feeding or Eating Disorders (OSFED) is often difficult for non-specialist clinicians. A main factor differentiating binge-purge anorexia from bulimia is the gap in physical weight. Patients with bulimia nervosa are ordinarily at a healthy weight, or slightly overweight. Patients with binge-purge anorexia are commonly underweight. Moreover, patients with the binge-purging subtype may be significantly underweight and typically do not binge-eat large amounts of food. In contrast, those with bulimia nervosa tend to binge large amounts of food. It is not unusual for patients with an eating disorder to "move through" various diagnoses as their behavior and beliefs change over time.
On 21 September, Pakistan launched airstrikes on the provinces of Paktika and Kunar in retaliation for the Kohat attack. Kunar's Nurgal district was hit at 4:00 local time, striking a family home and killing three family members and four others. Paktika's Barmal district was hit at 3:00, a shop and an unoccupied house were destroyed in the bombardment. Pakistani authorities denied striking civilians and said the attacks struck militant hideouts perfectly, supposedly killing 28 militants and multiple suicide bombers. On 22 September, it was reported that several Pakistani Taliban members attempted to cross the border at Kurram from Nangarhar and Paktia in Afghanistan. After being identified by Pakistani troops, they reportedly began firing on Pakistani checkposts. In retaliation, Pakistani troops launched multiple attacks on Afghan checkposts and defensive positions, supposedly causing several to flee. On 23 September, there were supposedly drone strikes inside Pakistan. While Pakistan blamed Afghanistan, Taliban officials denied the use of drones. On 24 September, Pakistan carried out airstrikes on 10 sites in Afghanistan. Kandahar, Paktia and Khost were struck and at least four civilians were killed. Afghanistan vowed to respond. The same day, local Afghan sources like Hariyat Media claimed that a Pakistani drone was intercepted over the Garmsir district near a Taliban border brigade position. On 27 September, Afghanistan's Defence Ministry claimed that 28 fighters were killed in Nuristan who had crossed the border from Pakistan.
Many types of benign tumors have the potential to become cancerous (malignant) through a process known as tumor progression. For this reason and other possible harms, some benign tumors are removed by surgery. When removed, benign tumors usually do not return. Exceptions to this rule may indicate malignant transformation.
=== Blood for Britain === The Blood for Britain program during the early 1940s was quite successful (and popular in the United States) based on Charles Drew's contribution. A large project began in August 1940 to collect blood in New York City hospitals for the export of plasma to Britain. Drew was appointed medical supervisor of the "Plasma for Britain" project. His notable contribution at this time was to transform the test tube methods of many blood researchers into the first successful mass production techniques. Nevertheless, the decision was made to develop a dried plasma package for the armed forces as it would reduce breakage and make the transportation, packaging, and storage much simpler. The resulting dried plasma package came in two tin cans containing 400 cc bottles. One bottle contained enough distilled water to reconstitute the dried plasma contained within the other bottle. In about three minutes, the plasma would be ready to use and could stay fresh for around four hours. The Blood for Britain program operated successfully for five months, with total collections of almost 15,000 people donating blood, and with over 5,500 vials of blood plasma. Following the Supplying Blood Plasma to England project, Drew was named director of the Red Cross blood bank and assistant director of the National Research Council, in charge of blood collection for the United States Army and Navy. Drew argued against the armed forces directive that blood/plasma was to be separated by the race of the donor.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.